[1]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82-85.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(03):82-85.[doi:10.3969/j.issn.1006-1959.2019.03.025]
点击复制

中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年03期
页码:
82-85
栏目:
论著
出版日期:
2019-02-01

文章信息/Info

Title:
Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer
文章编号:
1006-1959（2019）03-0082-04
作者:
吴森林; 高 斌
（安徽医科大学第三附属医院介入科，安徽 合肥 230000）
Author(s):
WU Sen-lin; GAO Bin
(Department of Intervention,the Third Affiliated Hospital of Anhui Medical University,Hefei 230000,Anhui,China)
关键词:
中性粒细胞/淋巴细胞比值; 非小细胞肺癌; 介入治疗; 生存时间
Keywords:
Neutrophil/lymphocyte ratio; Non-small cell lung cancer; Interventional therapy;  Survival time
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2019.03.025
文献标志码:
A
摘要:
目的 探讨介入治疗中晚期非小细胞肺癌（NSCLC）的患者的中性粒细胞/淋巴细胞比值（NLR）与其预后的相关性。方法 回顾性分析我院介入科2014年1月1日~2017年1月1日收治的68例行介入治疗的中晚期非小细胞肺癌患者的临床资料。计算术前NLR值，并通过建立ROC生存曲线分为高NLR组（NLR≥3.8）和低NLR组（NLR＜3.8），比较两组的无进展生存时间及总生存时间，同时对可能影响患者预后的危险因素行单因素及多因素分析。结果 所有患者在接受介入治疗后，中位总生存时间为421 d；其中高NLR组中位总生存时间为292 d，低NLR组中位总生存时间为506 d，差异有统计学意义（P＜0.05）；同时高NLR组中位无进展生存时间为152 d，低NLR组中位无进展生存时间为341 d，差异有统计学意义（P＜0.05）。在单因素分析中，存在远处转移、介入手术次数＜3次及NLR≥3.8均是影响总生存时间和无进展生存时间的危险因素（P＜0.05）；在多因素分析中，存在远处转移、NLR≥3.8是影响总生存时间的独立危险因素（P＜0.05）；存在远处转移、介入手术次数＜3次及NLR≥3.8是影响无进展生存时间的独立危险因素（P＜0.05）。结论 术前NLR可作为介入治疗中晚期NSCLC患者的预后指标，NLR高者预后差。
Abstract:
Objective To investigate the correlation between neutrophil/lymphocyte ratio (NLR) and prognosis in patients with advanced non-small cell lung cancer (NSCLC). Methods The clinical data of 68 patients with advanced non-small cell lung cancer who underwent interventional therapy from January 1, 2014 to January 1, 2017 were retrospectively analyzed. The preoperative NLR values were calculated and divided into high NLR group (NLR≥3.8) and low NLR group(NLR<3.8) by establishing ROC survival curve. The progression-free survival time and total survival time of the two groups were compared, and the patients may be affected. The prognostic risk factors were analyzed by single factor and multivariate factors. Results The median overall survival was 421 d in all patients after interventional therapy. The median overall survival was 292 d in the high NLR group and 506 d in the low NLR group,the difference was statistically significant(P<0.05); at the same time, the median progression-free survival time was 152 d in the high NLR group and 341 d in the low NLR group, the difference was statistically significant(P<0.05). In the univariate analysis, the presence of distant metastasis, the number of interventional procedures <3 times and NLR ≥ 3.8 were risk factors affecting the overall survival time and progression-free survival time (P<0.05); in the multivariate analysis, there was a distant place. Metastasis and NLR≥3.8 were independent risk factors for the overall survival time(P<0.05). The presence of distant metastasis, the number of interventional procedures <3 times and NLR≥3.8 were independent risk factors for progression-free survival(P<0.05).Conclusion Preoperative NLR can be used as a prognostic indicator for patients with advanced NSCLC. The prognosis of NLR is poor.

参考文献/References:


[1]Li W,Dan G,Jiang J,et al.Repeated iodine-125 seed implantations combined with external beam radiotherapy for the treatment of locally recurrent or metastatic stageⅢ/Ⅳ non-small cell lung cancer：A retrospective study[J].Radiat Oncol,2016(11):119.
[2]Huo X,Huo B,Wang H,et al.Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage Ⅲ non-small cell lung cancer[J].Journal of Contemporary Brachytherapy,2017,9(6):527-534.
[3]矫德馨,贾鉴慧,张旭.支气管肺动脉灌注＋栓塞化疗同步三维适形放疗治疗进展期中央型非小细胞肺癌的临床研究[J].实用医院临床杂志,2015,12(2):40-44.
[4]宿濛,秦宝丽.DC-CIK技术联合奥沙利铂、吉西他滨化疗治疗进展期中央型非小细胞肺癌的临床研究[J].现代仪器与医疗,2015,21(2):31-34.
[5]Xin LL,Nan S,Yi D,et al.Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells[J].Int Immunopharmacol,2015,25(2):156-157.
[6]Fang ZY,Lian NC,Li LJ,et al.Prognostic values of preoperative neutrophil－lymphocyte ratio and Glasgow prognostic score in non－small cell lung cancer patients[J].Modern Oncology,2016,24(8):1221-1223.
[7]孟玲楠,石砂硼,林珊,等.不同放化疗模式治疗中晚期非小细胞肺癌的疗效分析[J].现代生物医学进展,2016,11(29):5658-5662.
[8]陈彬．华蟾素联合GP方案治疗中晚期非小细胞肺癌的临床疗效和抗肿瘤机理[J].实用癌症杂志,2016,31(2):224-227.
[9]Tyson LB.Nonsmall cell lung cancer: new hope for a chronic illness[J].Oncol Nurs Forum,2007,34(5):963-970.
[10]Guthrie GJ,Charles KA,Roxburgh CS,et al.The systemic inflammation-based neutrophil-lymphocyte ratio:experience in patients with cancer[J].Crit Rev Oncol Hematol,2013,88(1):218-230.
[11]Li QQ,Lu ZH,Yang L,et al.Neutrophil count and the inflammation-based Glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy[J].Asian Pac J Cancer Prev,2014,15(2):945-950.
[12]Pauken KE,Wherry EJ.Overcoming T cell exhaustion in infection and cancer[J].Trends Immunol,2015,36(4):265-276.
[13]Sonpavde G,Pond GR,Armstrong AJ,et al.Prognostic Impact of the Neutrophil to Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer[J].Clin Genitourin Cancer,2014,12(5):317-324.
[14]Grenader T,Waddell T,Peckitt C,et al.Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer:Exploratory analysis of the REAL-2 trial[J].Ann Oncol,2016,27(4):687-692.
[15]Lorente D,Mateo J,Templeton AJ,et al.Baseline neutrophil-lymphocyte ratio(NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use[J].Ann Oncol,2015,26(4):750-755.
[16]Mizunuma M,Yokoyama Y,Futagami M,et al.The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer[J].Int J Clin Oncol,2015,20(5):989-996.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(03):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]何冬兰,李 文.NLR、PLR在慢性阻塞性肺疾病进展、预后中的相关研究[J].医学信息,2022,35(11):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
　HE Dong-lan,LI Wen.Study on Correlation Between NLR and PLR in the Progression and Prognosis of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(03):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
[4]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(03):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[5]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(03):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(03):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(03):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(03):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(03):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(03):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 2019-02-25